Obesity is a major risk factor for many chronic diseases, especially non-insulin dependent diabetes mellitus (NIDDM), coronary heart disease (CHD), gallstones and certain cancers. In addition, it exacerbates other conditions such as hypertension, dyslipidaemia and arthritis. 1 In New Zealand, as in many other countries, obesity is increasing despite ongoing health promotion aimed at reducing dietary fat, increasing physical activity and improvements in other cardiovascular risk factors. 2 In the decade 1982-1993/4 the prevalence of obesity, defined as a body mass index (BMI) greater than 30 kg/m 2 , increased by over 50% among 35-64 year-olds living in Auckland (8.8% to 14% for males and 9.5% to 13.9% for females) 3 . Obesity and its consequences carry many costs. These include the direct costs of health care, the indirect costs of loss of production, the costs of attempting to lose weight and the human costs of suffering or shortened lives. A number of studies have attempted to estimate the costs of obesity. [4] [5] [6] [7] [8] While such estimates are clearly crude, they provide one approach to synthesizing the public health impact of obesity. This information is critical when it comes to formulating health promotion and disease prevention priorities. Public health policy development and programme planning need to begin with these overall analyses, although for specific interventions, the marginal costs and benefits will need to be assessed for prioritising resources. 9 The focus of this study is on the (public and private) health care costs of the major obesity-related health problems.
The growing awareness of the magnitude of the increase in obesity prevalence has prompted several organisations in Australia to assess the health and economic cost of obesity and to call for a concerted public health campaign to reverse the trend. 5, 10, 11 A collaborative group of nutrition agencies in New Zealand (Agencies for Nutrition Action) has similarly identified the maintenance of healthy body weight as the major nutrition challenge for the foreseeable future. 12 This assessment of the cost of the obesity contributes to the existing knowledge base which in turn helps to shape public health policy. 
services provided for the treatment of obesity-related disorders. This figure is then multiplied by the proportion of each disorder that is attributable to obesity. Six conditions for which reasonable information is available have been recognised as being important contributors to the health-care costs of obesity: NIDDM, CHD (excluding hypertension), hypertension, gallstones, colon cancer and postmenopausal breast cancer. 4 The population attributable fraction (PAF) for each condition is the proportion of the condition which is attributable to obesity. It is a function of the relative risk (rr) and the prevalence of obesity 5 Differences in the prevalence of obesity and health care costs were assumed to be the main source of variation from these countries.
The prevalence of obesity (BMI
) for the population in 1991 was taken from two sources: the Life in New Zealand study 17 (n 3204), which reported a prevalence of 13.1% for men and 14.7% for women aged 25-65 y, and the Auckland Heart and Health Survey of 1993/4 (N 2518) which showed a prevalence of 13.8% for men and 15.6% for women aged 35-84 y. 3 An overall value of 14% was therefore used as the prevalence of obesity in the population developing obesity-related diseases. For post-menopausal breast cancer, a prevalence of 18% was used for females aged 50-84 y (Auckland Heart and Health Survey).
The health care costs of the six condition were estimated under the following cost categories: inpatient services (public and private hospitals), outpatient visits, general practitioner visits, pharmaceuticals, laboratory tests and ambulance services. Most of the figures are only best estimates, but all have been made on the conservative side when there has been uncertainty. Cost and prevalence figures were taken as close to 1991 as possible. Where necessary, costs were deflated to 1991 dollars using the consumer price index. While less than ideal, this index was used in the absence of any index devoted specifically to price changes in the health sector. All costs are in New Zealand dollars (in July 1991, NZ$1 US$0.58).
Inpatient costs
Volumes of public and private inpatient hospital services were derived, except where indicated, from 1991 diagnosis related groups (DRG) or from International Classification of Diseases (ICD) discharge and operation statistics. 19 These volumes were then multiplied by the respective DRG cost per admission or procedure for public hospitals in New Zealand. 18 Private hospital costs were assumed to be equal to these public hospital costs for the same admissions and procedures. The majority of secondary and tertiary health services in New Zealand are in public hospitals funded from general taxation and the minority are in private hospitals. For CHD, volumes of public inpatient services were estimated from coronary artery bypass operations (DRG codes 106, 107), angina (140), myocardial infarction (121-123), 25% of pacemaker implants (115-118), 75% of heart failure (127) and 50% of atherosclerosis (132-133). 22 Added to this were angiocardiography (ICD 855) and angioplasty (from individual centres), multiplied by the 1991 costs for these procedures. For private hospitals, inpatient volumes for CHD were based on ICD procedures for coronary angiography and bypass operations (360, 361, 885), pacemakers (25% of 377-378) and ICD inpatient discharges for ischaemic heart disease (410-414) and heart failure (75% of 428). These ICD volumes were then multiplied by the unit cost for each equivalent DRG.
For hypertension, DRG 134 was used for volumes of public hospital services and ICDs 401-404 (hypertension diagnoses) for private hospital services. Total cholecystectomy ) was the only discharge diagnosis costed for gallstones, although gallstones would also have been responsible for a number
were multiplied by 0.71 (n 1135) being the proportion presumed to be post-menopausal (age > 50 y). 23 The inpatient costs for public and private admissions were estimated to be $10 096 per patient. 24 This method gave similar volumes to the post-menopausal breast cancer operations from the DRG codes 257-260, 274-275 (mastectomies and malignant breast disease, n 1283) but the more detailed costing analyses 24 were considered more accurate than DRG costs (mean $4118 per admission). Colon cancer is not specified in the DRGs and therefore we used ICD 153 (malignant neoplasm of the colon) for both public and private hospital discharges and multiplied this by the weighted mean cost for DRGs 148 and 149 (major small or large bowel procedures).
Outpatient costs
For NIDDM, the number of outpatient visits was difficult to assess because of the wide variety of hospital outpatient services used by people with NIDDM. In 1991, 46 new NIDDM patients began dialysis (approximately 55% on continuous ambulatory peritoneal dialysis and 45% on haemodialysis) joining the 112 NIDDM patients already on dialysis. 25 These were multiplied by the annual cost per patient for these treatments. The national costs for general outpatient treatment for NIDDM were based on the Auckland Healthcare costs for total diabetes outpatient services for central Auckland. This was multiplied by 0.58 being the estimated NIDDM/IDDM proportion of use of services, then by 8.33 because the central Auckland area contains approximately 12% of the country's NIDDM patients. 26 For eye services used by people with NIDDM, estimates were made from the costs of South Auckland eye services, about 40% of which was attributed to diabetes and 80% of that to NIDDM (G Clover, personal communication). These were then extrapolated nationally to give an approximate figure for New Zealand. No adjustments were made for the age structure, ethnic mix or proportion of public=private eye service use.
The outpatient costs for CHD were taken from Scott et al 27 , and for hypertension, the costs were taken from four hypertension clinics in New Zealand. For gallstones (n 3694) and colon cancer (n 1420), it was assumed that on average there would be three and six outpatient visits respectively. The costs of surgical outpatient visits were estimated from the 1991 Auckland Healthcare non-resident charges ($200 for initial visit and $135 for subsequent visits) minus 25% mark up to derive costs. For post-menopausal breast cancer, the outpatient cost ($1263 per patient) included diagnostic and referral consultations as well as the cost of prostheses and wigs for those who received chemotherapy. 24 Any patient copayments are included in these outpatient costs.
General practitioner costs
The average cost of a visit to a general practitioner (GP) in 1991 was taken as $27.56. 27 This comprises any government subsidy plus patient copayment (net of tax). A survey conducted in 1991/92 28 found that 1.5/100 GP consultations were for diabetes. Of these, 95% were assumed to be for NIDDM. The survey also found that 6/100 visits were for hypertension and 2.9 were for CHD. From the mean of 109 total consultations per GP per week, we estimated the annual consultations to be 5232 (assuming a 48 week year). This was multiplied by the number of fulltime equivalent GPs in 1991 (2321) and the above rates for NIDDM, hypertension and CHD were then applied. Five consultations 24 were allocated for each case of post-menopausal breast cancer (n 1135), 23 while three follow up consultations were allocated to colon cancer (n 1420), 23 and cholecystectomy (n 3694).
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Pharmaceutical costs
Except in the case of breast cancer, pharmaceutical costs were estimated by adding together the government subsidies and patient copayments for the pharmaceuticals used for each condition in 1991 (Health Benefits Wanganui Ltd). The copyaments were allocated according to the proportion of subsidised dispensings which incurred each of the different levels of patient charges. No pharmaceutical costs could be allocated for colon cancer or gallstone disease.
Diabetes pharmaceuticals included all oral agents and 20% of hypoglycaemic treatments and 60% of insulin and needles. 29 For CHD, we included lipidlowering drugs, loop diuretics, cardiac glycosides, nitrates, vasodilators and thrombolytic drugs, 75% of antiplatelet drugs and 50% of antiarrythmics, anticoagulants and sympathomimetics. Drugs for hypertension were non-loop diuretics, beta blockers, calcium channel blockers, ACE inhibitors, alpha blockers, centrally-acting agents, adrenergic neurone blockers, and various vasodilators. It was assumed that each GP visit for NIDDM, hypertension, and CHD incurred a prescription for one drug and the above proportions were then applied. The pharmaceutical costs for breast cancer were determined from a review of medical records of a group of patients with breast cancer and assessed at tamoxifen for two thirds of patients, and chemotherapy (six doses of fluorouracil, adriamycin, cyclophosphamide) for 30% of patients ($1115 per patient, including any copayments).
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Laboratory costs
Total government expenditure on laboratory services amounted to about $88.9m in 1991/92. 27 Of this, 1.1% was assumed to be for fructosamine, glucose and glucose tolerance tests, this being the proportion of the total reimbursement for one community laboratory that was accounted for by these tests. Eighty per cent of this amount was assumed to be for NIDDM. A B S w i n b u r n e t a l 8 9
casual glucose estimation carries a user charge of $6 and we estimated that about 200 000 of these tests would be done annually. This equates to an average of about 4 tests per NIDDM patient per year and is similar to previous estimates. 26 To cover the other laboratory costs of NIDDM, such as other urine and blood tests, we allocated a conservative $20 per person with NIDDM. For CHD, we used the estimate made by Scott et al of all lipid and cardiac enzymes plus one third of urea and electrolytes which they assessed at 5% of total laboratory expenditure ($4.4m). 27 For each case of breast cancer, the costs of blood tests, fine needle aspiration and diagnostic mammography were estimated at $2678. 24 Each case of colon cancer and cholecystectomy, was allocated one barium enema ($200) and one abdominal ultrasound ($181) respectively. No laboratory costs were allocated for hypertension.
Ambulance costs
The ambulance attendance for CHD in 1991 were taken from estimates by Scott et al. 27 Ambulance costs for the other conditions (which would include acute cholecystitis, diabetic emergencies and abdominal emergencies from bowel cancer) have not been included.
R e s u l t s
The estimated 1991 health care costs for the six obesity-related conditions analysed were approximately NZ$409m ( Table 1 ). The amount attributable to obesity for each of the six conditions is shown in Table 2 . The total amount attributable to obesity is estimated to be approximately NZ$135m (equivalent to about US$77.7) for a population of about 3.4 million. The two conditions with the closest relationship to obesity were NIDDM and gallstones (69% and 56% contribution, respectively). However, because of the greater numbers involved, CHD and hypertension combined with NIDDM were the three main contributors to the total cost of obesity ($41m, $37m and $42m respectively).
This study provides a snapshot of the estimated costs of obesity in a single year. As such, it provides an indication of the size of the problem and the potential for savings which could flow from a reduction in the prevalence of obesity. However prevention policies incur costs of their own and these costs need to be weighed up against any potential savings. Estimating health care costs with incomplete data always involves a large number of assumptions and this study is no exception. We have tried to make these assumptions as realistic and as clear as possible, but always erring on the conservative side. Because secondary sources of cost data were used, it was sometimes difficult to assess the accuracy of these costs. In particular, no breakdown was available for inpatient hospital costs. 18 The accuracy of the overall estimates could have been increased by using age and gender specific analyses for prevalence, relative risks and volumes, but unfortunately this level of detailed 
data was not available, particularly for DRG volumes, and the relative risk estimates were already ageadjusted. The estimated costs of CHD ($170m) were similar to earlier estimates of $178m for 1991, 27 and the costs of hypertension were probably robust because they were mainly drug costs for which the data were well documented. These were two of the biggest contributors to the overall cost. Data on the number of operations for gallstones and the two cancers assessed were also probably robust, but the other costs for these conditions involved a large number of assumptions.
The costs for NIDDM were probably the least robust and most underestimated because NIDDM as a multisystem disease gets classified under a wide variety of diagnoses. People with diabetes are more likely to be admitted for most diagnoses and they stay longer in hospital. 30 These diabetes volumes are likely to be considerable underestimates because diabetes is frequently under-reported 30 and people with diabetes are more likely to be admitted and stay longer for most disease categories. 31 The total cost of NIDDM in New Zealand is undoubtedly several-fold higher than the $61m shown in Table 1 . A substantial proportion of the real total costs of NIDDM (perhaps up to 50%) would be categorised in this study under CHD and hypertension. 30 If other estimates of diabetes consuming 4-5% total health care expenditure are correct, 32 the New Zealand costs could be between $200-$300 million.
International comparisons of the costs of obesity may provide useful verification of the results of this study but they need to be normalised to account for differences in populations and health care systems and costs. An Australian estimate of the 1991 costs of obesity (for the same six conditions as the current study) was A$366 million. 5 This represents a cost of about NZ$28m per million Australians. The costs in the present study were about NZ$39m per million New Zealanders. The proportion each condition contributed to the total differed between the estimates in the two countries. For example CHD contributed to 42% of the New Zealand total compared to 29% of the Australian total. Given the crudeness of the estimates, however, it is important not to overinterpret such differences.
The $135m estimated costs of obesity in this study represents about 2.5% of the total (public and private) health care expenditure. 33 This compares with an Australian estimate using similar methodology of 2%, 5 a Dutch estimate of 4% (1% for obesity and 3% for overweight) 6 and a French estimate of 2%. 8 Estimates of direct plus some indirect costs range between about 5.5% and 8%. 4, 34 These latter studies use the cost of illness rather than health expenditure as the denominator.
It is important to note the areas which were underestimated or not covered in this study (Table 3 ). The direct cost estimates contained many examples of underestimation. The costs of NIDDM did not include costs of important complications such as neuropathy and infections. The drug costs for gallstones and colon cancer could not be assessed. For breast and colon cancer, the costs of recurrences and of hospice care, for those who needed it, could not be estimated but were likely to be substantial. The costs of testing strips for diabetes were not included and nor were any costs allocated to health care from other health professionals such as district nurses and dietitians. It is also likely that the diseases assessed are more severe (and, thus, more costly) among the obese.
Other costs attributable to obesity are difficult to assess and have not been included in this analysis (Table 3) . Other obesity-related conditions which were not assessed include stroke, arthritis, other cancers (endometrial, gallbaldder, prostate, ovarian) and gout. Of these, the condition likely to contribute the greatest extra obesity-related costs is arthritis. When Colditz 4 extrapolated the obesity contribution to osteoarthritis of the knee (about 50%) to all musculoskeletal disorders his estimates for the total costs of obesity in the US increased from US$39 billion to US$56 billion. We used a definition of obesity as a BMI over 30 13, 15, 35 The costs of treatment of obesity itself in New Zealand are unknown but are likely to be substantial.
The indirect costs of loss of production and intangible costs (such as impaired quality of life) were not included in this study. Scott et al 27 estimated that the indirect and intangible (loss of life only) costs for CHD added 80-180% to the direct costs. For obesity and its related conditions, the loss of production and other indirect costs would be substantial. Obesity also shortens lives and one Australian study estimated that death due to obesity (BMI > 30 kg/m 2 ) resulted in about 13 000 potential years of life lost before age 65 and 30 000 potential years of life lost before age 75. 5 The impaired quality of life caused by obesity, 
while difficult to measure, is enormous 36 and, on a population level, should probably include eating disorders.
The estimate that the health care costs of obesity are at least $135m and will be increasing as the prevalence of obesity increases gives added impetus to achieving the goal in the Ministry of Health's Nutrition Plan of Action to prevent further increases in the prevalence of obesity. 37 
